Clinical Research

Adjustable interatrial shunt for heart failure shows promise in first-in-human trial
Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.
Beta-blockers do not benefit heart attack patients with a normal LVEF
The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.
Drones deliver AEDs for the first time in the United States
“This study represents a major step forward in how we respond to cardiac arrest in the United States,” explained Monique Starks, MD, principal investigator. “By integrating drone technology into emergency care, we’re working to close the critical gap between cardiac arrest and treatment."
Early TAVR for asymptomatic severe AS cuts costs, improves outcomes
The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.
Winning cash for taking blood pressure meds increases compliance
About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

Gregg W. Stone, MD, Director of Academic Affairs for the Mount Sinai Health System and Professor of Medicine (Cardiology) and Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai, discusses the ATHENS-HF Trial, a first-in-man study of a chronically-adjustbable, bi-atrial pressure sensing inter-atrial shunt from Adona Medical.

Adjustable interatrial shunt for heart failure shows promise in first-in-human trial

Gregg Stone, MD, spoke to Cardiovascular Business about early data from the ATHENS-HF trial. Ten heart failure patients were treated with the adjustable device, and each implant was a success.

Beta-blockers do not benefit heart attack patients with a normal LVEF

The new meta-analysis included data from nearly 18,000 patients. Overall, patient outcomes were quite similar for patients who did and did not undergo beta-blocker therapy.

Duke University is heading a project that for the first time in the United States, drones will be used to quickly deliver automated external defibrillators (AEDs) to bystanders who call 911 for patients in cardiac arrest. The idea is to deliver an AED faster than police or paramedics could arrive on scene, saving critical minutes in an effort to boost survival.

Drones deliver AEDs for the first time in the United States

“This study represents a major step forward in how we respond to cardiac arrest in the United States,” explained Monique Starks, MD, principal investigator. “By integrating drone technology into emergency care, we’re working to close the critical gap between cardiac arrest and treatment."

Early TAVR for asymptomatic severe AS cuts costs, improves outcomes

The study found lifetime per-patient savings from early TAVR ranged from about $2,334 in the U.K. to $19,607 in Switzerland.

Winning cash for taking blood pressure meds increases compliance

About 71% of patients in the rewards group opened their blood pressure medication on 80% of days, compared with about 34% in the control group.

Meril Life Sciences, an India-based medical device company founded in 2006, developed the Myval TAVR valve

Myval TAVR valve outperforms Sapien and Evolut in the late-breaking LANDMARK trial

The LANDMARK trial continues to show positive outcomes for the TAVR valve made in India.

Drinking coffee may reduce risk of recurrent AFib

Physicians often tell AFib patients they should limit coffee consumption to protect their hearts. This new analysis, however, suggests that may not be necessary.

AI-enabled coronary plaque quantification outperforms traditional risk scores

Researchers used AI-enabled software developed by Cleerly to evaluate the CCTA results of more than 6,000 patients. The software was consistently effective, identifying patients who may face an increased risk of poor outcomes.